Division of Metabolism and Endocrinology, Department of Internal Medicine, St. Marianna University School of Medicine, Kanagawa, Japan
Research Paper
The effectiveness of Sitagliptin vs ipragliflozin for type 2 diabetes
Author(s): Atsuko M, Yasuo T, Yasushi T, Masaaki M, Hideaki K, Nobuo S, Mitsuo O, Masashi I, Kazuhiko H, Sachio A, Akira K, Taro A, Keiji T, Hideo M, Tetsuro T, Matsuba I*, Mizuki K, Hikaru A, Taisuke K, Shogo I, Hiroshi T, Akira K, Shinichi U, Nobuaki M, Shigeru N, Masahiko T, Masahiro T, Takashi I, Takehiro K and Kotaro I
Background: There have been direct comparisons of dipeptidyl peptidase-4 inhibitors and sodium-glucose cotransporter-2 inhibitors in Japanese patients with type 2 diabetes.
Methods: We retrospectively assessed the effects of 24-week treatment with sitagliptin (a dipeptidyl peptidase-4 inhibitor) in the ASSET-K study or 24-week treatment with ipragliflozin (a sodium-glucose cotransporter-2 inhibitor) in the ASSIGN-K study. In both studies, patients with poor glycemic control received the study drug in addition to standard care with/without other antidiabetic medications or were switched to the study drug. The effects of each drug on metabolic risk factors (body weight, blood glucose, and lipids), blood pressure, and renal function were compared.
Results: After 4 weeks of treatment, hemoglobin A1c was significantly lower.. View More»
